When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
Aimmune (AIMT) has been on my 2019 watch list, but the stock's premium price prevented me from committing to a buy. Now, the recent sell-off has AIMT near the top of my shopping list. The company is in the process of launching their first FDA-approved product, Palforzia, for the mitigation of allergic reactions for peanut-allergic patients. I believe AIMT is worthy of a pilot position at these prices.
I will discuss my view on Palforzia and how Aimmune is planning to transition into a commercial company. In addition, I discuss why I am looking to